A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction

The purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with reduced ejection fraction.

Start Date13 Feb 2024

Sponsor / Collaborator

Cardurion Pharmaceuticals, Inc.

NCT06215586

/ CompletedPhase 2

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Preserved Ejection Fraction

The purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with preserved ejection fraction

Start Date13 Feb 2024

Sponsor / Collaborator

Cardurion Pharmaceuticals, Inc.

NCT05312021

/ WithdrawnPhase 2

Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction: a Safety and Efficacy Phase 2 Randomized Clinical Study (SP9In-HFpEF)

This study is to evaluate whether 16 weeks of treatment with IMR-687 is a safe and effective treatment for patients with Heart Failure with Preserved Ejection Fraction (HFpEF). The primary objective is to evaluate whether IMR-687 reduces NT-proBNP compared to placebo in these patients.

Start Date01 Apr 2022

Sponsor / Collaborator

Cardurion Pharmaceuticals, Inc.

[+1]

100 Clinical Results associated with Tovinontrine

100 Translational Medicine associated with Tovinontrine

100 Patents (Medical) associated with Tovinontrine

Literatures (Medical) associated with Tovinontrine

10 Dec 2021·Hematology. American Society of Hematology. Education ProgramQ3 · EDUCATION

β-Thalassemia: evolving treatment options beyond transfusion and iron chelation

Q3 · EDUCATION

Review

Author: Langer, Arielle L. ; Esrick, Erica B.

Abstract:

After years of reliance on transfusion alone to address anemia and suppress ineffective erythropoiesis in β-thalassemia, many new therapies are now in development. Luspatercept, a transforming growth factor–β inhibitor, has demonstrated efficacy in reducing ineffective erythropoiesis, improving anemia, and possibly reducing iron loading. However, many patients do not respond to luspatercept, so additional therapeutics are needed. Several medications in development aim to induce hemoglobin F (HbF): sirolimus, benserazide, and IMR-687 (a phosphodiesterase 9 inhibitor). Another group of agents seeks to ameliorate ineffective erythropoiesis and improve anemia by targeting abnormal iron metabolism in thalassemia: apotransferrin, VIT-2763 (a ferroportin inhibitor), PTG-300 (a hepcidin mimetic), and an erythroferrone antibody in early development. Mitapivat, a pyruvate kinase activator, represents a unique mechanism to mitigate ineffective erythropoiesis. Genetically modified autologous hematopoietic stem cell transplantation offers the potential for lifelong transfusion independence. Through a gene addition approach, lentiviral vectors have been used to introduce a β-globin gene into autologous hematopoietic stem cells. One such product, betibeglogene autotemcel (beti-cel), has reached phase 3 trials with promising results. In addition, 2 gene editing techniques (CRISPR-Cas9 and zinc-finger nucleases) are under investigation as a means to silence BCL11A to induce HbF with agents designated CTX001 and ST-400, respectively. Results from the many clinical trials for these agents will yield results in the next few years, which may end the era of relying on transfusion alone as the mainstay of thalassemia therapy.

News (Medical) associated with Tovinontrine

18 Sep 2026

·www.prnewswire.com

HFSA's 2026 Annual Scientific Meeting to Feature Late-Breaking Trials That Could Reshape Heart Failure Treatment

October 9-12, 2026 | Phoenix, Arizona -- New data spans pharmacotherapy, imaging and diagnostics, and device therapy for patients with cardiomyopathy Continue Reading These trials ... represent some of the most anticipated data in ... medicine for patients with cardiomyopathy this year. Post this The HFSA Annual Scientific Meeting takes place October 9-12, 2026 in Phoenix, Arizona. WASHINGTON, Sept. 18, 2026 /PRNewswire/ -- The Heart Failure Society of America (HFSA) today announced the Late-Breaking Clinical Research slate for its Annual Scientific Meeting (ASM), October 9-12, 2026, at the Phoenix Convention Center in Phoenix, Arizona. This year's late-breaking program spans pharmacotherapy, imaging and diagnostics, and device-based therapy - including new data on whether a novel oral therapy could establish an additional treatment pillar for both HFrEF and HFpEF, a first-of-its-kind imaging approach designed to detect cardiac amyloidosis without an invasive biopsy, and real-world outcomes from established device therapies. View all late-breaking science below and online. "This year's Late-Breaking Science program reflects the pace of innovation transforming heart failure care," said Jennifer Thibodeau, MD, MSCS, 2026 HFSA Annual Scientific Meeting Program Committee Chair. "These trials showcase advances in pharmacotherapy, imaging and diagnostics, as well as device therapy, and represent some of the most anticipated data in cardiovascular medicine for patients with cardiomyopathy this year." Late-breaking clinical research to be featured during two plenary sessions includes results and updates from these major randomized trials: Sunday, October 11 Plenary Session | 9:00 AM – 10:30 AM Late-Breaking Evidence from Novel Therapies to Real-World Outcomes Cycle-1 REF A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction: The Cycle-1 REF Trial Cycle-2 PEF A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Clinical Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Preserved Ejection Fraction: The Cycle-2 PEF Trial CARDIO-TTRansform Effect of Eplontersen on Health Status in Patients with Transthyretin Amyloid Cardiomyopathy Enrolled in the CARDIO-TTRansform Trial 124I-Evuzamitide Amyloid-targeted PET/CT Scan: Potential for Detection of Early Cardiac Amyloidosis in a Prospective Multicenter Phase 3 Study Cohort Cardiac Contractility Modulation Therapy One-Year Real-World Clinical Outcomes Following Cardiac Contractility Modulation Therapy from the U.S. Post-Approval Study REBALANCE The REBALANCE Registry: Real World Outcomes Following Baroreflex Activation Therapy Monday, October 12 Plenary Session | 9:00 AM – 10:30 AM Late-Breaking Evidence from Novel Therapies to Real-World Outcomes ACACIA-HCM Global Efficacy Of Aficamten In Nonobstructive Hypertrophic Cardiomyopathy: Results From ACACIA-HCM Aficamten Improves Comprehensive Measures of Exercise Performance in Non-Obstructive Hypertrophic Cardiomyopathy: A Prespecified Analysis of ACACIA-HCM POSEIDON Prevalence of Cardiovascular Inflammation and Associated Patient Characteristics and Biomarker Profiles Across the Heart Failure Spectrum in the United States: Results From the POSEIDON Study C-MIC III & C-MIC II Effects of Cardiac Microcurrent Therapy on Exercise Capacity: Independent Core Laboratory CPET Analysis of the C-MIC II Trial Six-Month Outcomes of Subcutaneous Cardiac Microcurrent Therapy: Comparative Analysis of the C-MIC III Pilot Study with the C-MIC II Randomized Trial Late-breaking clinical research showcases novel results of major randomized trials and rapidly evolving research. Due to the exceptional volume and quality of research submitted this year, HFSA will also feature late-breaking research through Rapid Fire Oral Sessions. These Rapid Fire sessions are fast-paced oral presentations spotlighting key data from late breaking clinical research. Sessions take place on Sunday and Monday with Q&A and new topics each day. Sunday, October 11 | Rapid Fire 1 | 10:45 AM - 11:45 AM Ratio of Serum Transthyretin to NT-proBNP is a Novel Prognostic Measure for Transthyretin Amyloid Cardiomyopathy: Insights From ATTRibute-CM Colchicine In Patients With Heart Failure And Preserved Ejection Fraction: A Crossover Trial The ReDS-SAFE HF II: Remote Dielectric Sensing-Guided Decongestion Strategy In Patients Hospitalized For Heart Failure. A Trial Design Early eGFR Decline Following Acoramidis Initiation is Associated With Reduced Risk of Recurrent Cardiovascular Hospitalizations and Mortality Gator SCALES-WHF: Sub-Cutaneous Administration of Lasix to Eliminate Symptoms of Worsening Heart Failure Real World Comparative Effectiveness Study of Acoramidis Versus Tafamidis in Transthyretin Amyloid Cardiomyopathy Using the Epic COSMOS Data Platform Dosing And Safety Of Aficamten For Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy In The ACACIA-HCM Trial Sunday, October 11 | Rapid Fire 2 | 2:30 PM - 3:30 PM Ambulatory Upright Pulmonary Artery Pressure and Risk of HF Hospitalization and Death in Patients with Chronic Heart Failure Hyperbaric Oxygen Therapy and EECP as Adjuvant Therapy in Heart Failure : A Prospective Interventional Study Baroreflex Activation Therapy in Heart Failure with Mildly Reduced Ejection Fraction: First Real-World Evidence of Reduced Hospitalization Burden Cost-Effectiveness Of ReDS-Guided Heart Failure Management Pulmonary Artery Pressure Response to Loop and Thiazide Diuretic Intensification in Heart Failure: Impact of Diuretic Class and Patient Characteristics Ambient Home Monitoring of Peripheral Oedema Significantly Reduces Heart Failure Events: Final Results from the Randomized HF-TRACK Trial Therapeutic Sequencing Is Projected to Improve Quality-Adjusted Survival in Heart Transplant Candidates with Advanced Heart Failure: A Risk-Selected Left Ventricular Assist Device-First Strategy Sunday, October 11 | Rapid Fire 3 | 5:00 PM - 6:00 PM Impact of Eplontersen on Cardiac Biomarkers in Participants with Transthyretin Amyloid Cardiomyopathy in the CARDIO-TTRansform Phase III Trial Weight Loss Surgery Impact on Comprehensive Metabolic Responses to Exercise in Heart Failure with Preserved Ejection Fraction Primary Results Trajectories of Dyspnea After Heart Failure Hospitalization: A Prospective Longitudinal Cohort Study Achieving Near Target-Dose Quadruple Guideline-Directed Medical Therapy Before Hospital Discharge After Acute Heart Failure: The STRONG-HF Japan Study Association of Quadruple Therapy Achievement and Biochemically Verified Medication Adherence with Outcomes in HFrEF: Insights from the POLY-HF Trial The Impact Of An Adaptive Patient-Centered Web Application on Medication Optimization In Patients With HFrEF: A Multicenter Randomized Trial Monday, October 12 | Rapid Fire 4 | 12:15 PM – 1:15 PM TAILORD Electronic Intervention to Improve Therapy in a Diverse Cohort of Patients with Heart Failure Post-ARIES Antithrombotic Implementation and Safety Evaluation in HeartMate 3 (PRAISE HM-3) EDG-15400, A Cardiac Sarcomere Modulator, Demonstrated Favorable Pharmacokinetics, Pharmacodynamics, and Tolerability in Healthy Adult Participants Rapid Non-invasive Sensors-Derived Assessment of Left Ventricular Filling Pressure in Patients Presenting With Acute Dyspnea Three-Year Results of PROACTIVE-HF Trial Stratified by Sex The meeting kicks off in just three weeks. A full schedule-at-a-glance is available online, as well as information on the science and research available at the meeting. Learn more about the meeting and register at hfsa.org/asm2026. Media Registration & Embargo Policy Credentialed and accredited media may register for complimentary press access to HFSA ASM 2026 by contacting Laura Poko at lpoko@hfsa.org. As part of HFSA's 24-Hour Press Access Window, credentialed and accredited media will receive embargoed access to press materials beginning 24 hours before each embargo lifts. During this period, media may review embargoed press releases, abstracts, and presenter details via a secure, password-protected folder, and schedule pre-embargo interviews with late-breaking science presenters. All interviews and materials remain strictly embargoed until the time of presentation listed above. Follow #HFSA2026 for real-time coverage from the meeting. About the Heart Failure Society of America The Heart Failure Society of America, Inc. (HFSA) represents the first organized effort by heart failure experts from the Americas to provide a forum for all those interested in heart function, heart failure, and congestive heart failure (CHF) research and patient care. The mission of HFSA is to provide a platform to improve and expand heart failure care through collaboration, education, innovation, research, and advocacy. HFSA members include physicians, scientists, nurses, nurse practitioners, pharmacists, trainees, other healthcare workers and patients. For more information, visit hfsa.org. Media Contact: Laura Poko, 301-798-4493, ext. 226, lpoko@hfsa.org SOURCE Heart Failure Society of America 21% more press release views with Request a Demo

27 Aug 2026

·www.biospace.com

Cardurion Pharmaceuticals Announces Late-Breaking Presentation of Phase 2 Results for Tovinontrine (CRD-750), a PDE9 Inhibitor, in Heart Failure

Results from two Phase 2 clinical trials assessing tovinontrine in both major types of chronic heart failure will be presented at the Heart Failure Society of America annual scientific meeting BURLINGTON, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Cardurion Pharmaceuticals , Inc. (“Cardurion”), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of patients with cardiovascular diseases, today announced that the Company will present results from the Phase 2 CYCLE clinical trials evaluating tovinontrine (CRD-750), a novel phosphodiesterase-9 (PDE9) inhibitor, in chronic heart failure. The results will be presented in late-breaking presentations at the Heart Failure Society of America (HFSA) Annual Scientific Meeting in Phoenix, Arizona taking place on October 9–12, 2026. Tovinontrine is an orally administered PDE9 inhibitor that represents a new mechanism to enhance the natriuretic peptide signaling (NPS) pathway, a clinically validated pathway for the treatment of patients with heart failure. Cardurion is the first company to bring a PDE9 inhibitor into clinical development for the treatment of chronic heart failure. “We look forward to sharing the exciting results from our CYCLE trials, which represent the first time that robust Phase 2 data have been completed for PDE9 inhibition in heart failure. Despite current standard of care, a large unmet medical need remains, and patients with chronic heart failure continue to experience high rates of morbidity and mortality,” said Howard Surks, MD, Chief Medical and Scientific Officer of Cardurion. “It is a major milestone for our company to successfully complete this large, global clinical program in both major types of heart failure, and the results of the CYCLE studies will guide the next stage of clinical development for tovinontrine as we move closer to our goal of bringing this novel PDE9 inhibitor to patients with chronic heart failure.” The presentations at HFSA in October will describe the results from Cardurion’s global, multi-center, Phase 2 clinical trials ( NCT06215911 and NCT06215586 ) assessing the safety and efficacy of tovinontrine in the two major types of chronic heart failure : heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) . Details for the presentations at HFSA are as follows: CYCLE-1 REF presentation title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine (CRD-750) in Patients With Chronic Heart Failure With Reduced Ejection Fraction: The Cycle-1 REF Trial CYCLE-2 PEF presentation title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Clinical Study to Assess the Safety and Effectiveness of Tovinontrine (CRD-750) in Patients With Chronic Heart Failure With Preserved Ejection Fraction: The Cycle-2 PEF Trial About PDE9 Inhibition Phosphodiesterase (PDE) 9 is an enzyme whose elevated activity in patients with heart failure reduces the beneficial effects of the natriuretic peptide signaling (NPS) pathway. The NPS pathway plays an important and protective role in cardiac function, and its activation has been shown to confer outcomes benefit for patients with heart failure . PDE9 is significantly upregulated in patients with chronic heart failure, causing disruption in the NPS pathway. Cardurion is the first company to demonstrate clinical proof-of-mechanism for PDE9 inhibition in patients with chronic heart failure with its PDE9 program. About Heart Failure Heart failure is a prevalent and growing condition that is responsible for substantial morbidity and mortality. Approximately 6.7 million adults in the United States suffer from heart failure, and approximately 50 percent of these patients die from the condition within five years of diagnosis. One in five patients with heart failure are hospitalized annually, and approximately 25 percent of these patients are re-admitted within a month of discharge. Approximately half of all patients with chronic heart failure have reduced ejection fraction (HFrEF) and half have preserved ejection fraction (HFpEF), categorized as different diseases based on the pumping ability of the heart. Significant unmet medical needs remain in heart failure, despite the reductions in morbidity and mortality from currently approved treatments for heart failure. About Cardurion Pharmaceuticals Cardurion Pharmaceuticals is a clinical-stage biotechnology company discovering and developing new therapeutic approaches to address cardiovascular diseases. Cardurion has extensive expertise in cardiovascular biology, signaling pathways and drug discovery and development, and it translates that expertise into potentially groundbreaking therapeutics with the promise to address the unmet needs of patients. Cardurion’s clinical-stage pipeline consists of product candidates targeting phosphodiesterase-9 ( PDE9 ) and calcium/calmodulin-dependent protein kinase II ( CaMKII ). Cardurion is the first company to advance product candidates against these novel and important targets into clinical testing for the treatment of cardiovascular disease. Cardurion is headquartered in Burlington, Massachusetts, with discovery sciences and research facilities in Shonan, Japan. For more information, please visit Cardurion’s website at and follow us on LinkedIn . CONTACT: Contacts Investors: Charlie Newman Chief Business & Operating Officer charlie.newman@cardurion.com Media Contact: Kathryn Morris The Yates Network LLC kathryn@theyatesnetwork.com

08 Aug 2025

·www.globenewswire.com

Cardurion Pharmaceuticals Completes Enrollment in Phase 2 CYCLE Trials Evaluating CRD-750, a Novel PDE9 inhibitor, in Heart Failure

CRD-750 is the first clinical-stage PDE9 inhibitor to be evaluated in patients in both types of chronic heart failure The CYCLE-1-REF trial is evaluating patients with heart failure with reduced ejection fraction (HFrEF), and the CYCLE-2-PEF trial is evaluating patients with heart failure with preserved ejection fraction (HFpEF) Aug. 06, 2025 -- Cardurion Pharmaceuticals, Inc. (“Cardurion”), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of patients with cardiovascular diseases, today announced that it has completed enrollment in two global, multi-center, Phase 2 clinical trials assessing the safety and efficacy of CRD-750 in both types of chronic heart failure (HFrEF and HFpEF). CRD-750 is an orally-administered phosphodiesterase 9 (PDE9) inhibitor that represents a new mechanism to enhance the natriuretic peptide signaling (NPS) pathway, a clinically-validated pathway for the treatment of patients with heart failure. Cardurion is the first company to bring a PDE9 inhibitor into clinical development for the treatment of chronic heart failure. The CYCLE-1-REF trial (NCT06215911) enrolled approximately 560 patients with HFrEF and is evaluating three doses of CRD-750 compared to placebo. CYCLE-2-PEF (NCT06215586) enrolled approximately 300 patients with HFpEF and is evaluating one dose of CRD-750 compared to placebo. The primary endpoint of both CYCLE clinical trials is the change in N-terminal pro-B-type natriuretic peptide (NT-proBNP), a peptide that is released by the heart in the setting of heart failure. Reduction in NT-proBNP has been used as a biomarker to measure the treatment effect in clinical trials of other approved heart failure therapies. The trials are also evaluating secondary endpoints, including additional biomarkers and the Kansas City Cardiomyopathy Questionnaire (KCCQ), a patient-reported outcomes scale. “The clinical community eagerly awaits the results of the CYCLE clinical trials. Despite recent approvals, a large unmet medical need persists and patients with heart failure continue to experience high rates of morbidity and mortality. PDE9 inhibition is a promising new mechanism in the NPS pathway that may offer an opportunity to improve the standard of care treatment for the millions of patients with both types of chronic heart failure,” said James Udelson, MD, Chief of Cardiology at Tufts Medical Center and Principal Investigator for the CYCLE-1-REF and CYCLE-2-PEF trials. “Completion of enrollment in the CYCLE trials represents a major milestone in our CRD-750 clinical program. Since the founding of Cardurion, our team has believed that the upregulation of PDE9 that occurs in heart failure is a critical element limiting the beneficial clinical effects of the highly validated NPS pathway. Our progress brings us closer to our goal of leveraging PDE9 inhibition to address unmet needs for patients,” said Howard Surks, MD, Chief Medical and Scientific Officer of Cardurion. “It is gratifying for us to implement this large, global clinical program in partnership with the cardiovascular treatment community. We look forward to receiving the Phase 2 results from these clinical trials and presenting them at a future medical meeting.” Phosphodiesterase (PDE) 9 is an enzyme whose elevated activity in patients with heart failure reduces the beneficial effects of the natriuretic peptide signaling (NPS) pathway. The NPS pathway plays an important and protective role in cardiac function and its activation has been shown to confer outcomes benefit for patients with heart failure. PDE9 is significantly upregulated in patients with chronic heart failure, causing disruption in the NPS pathway. Cardurion is the first company to demonstrate clinical proof-of-mechanism for PDE9 inhibition in patients with chronic heart failure with its PDE9 program. Heart failure is a prevalent and growing condition that is responsible for substantial morbidity and mortality. Approximately 6.7 million adults in the United States suffer from heart failure, and approximately 50 percent of these patients die from the condition within five years of diagnosis. One in five patients with heart failure are hospitalized annually, and approximately 25 percent of these patients are re-admitted within a month of discharge. Approximately half of all patients with chronic heart failure have reduced ejection fraction (HFrEF) and half have preserved ejection fraction (HFpEF), categorized as different diseases based on the pumping ability of the heart. Unmet medical needs remain in heart failure, despite the reductions in morbidity and mortality from currently approved treatments for heart failure. Cardurion Pharmaceuticals is a clinical-stage biotechnology company discovering and developing new therapeutic approaches to address cardiovascular diseases. Cardurion has extensive expertise in cardiovascular biology, signaling pathways and drug discovery and development, and it translates that expertise into potentially groundbreaking therapeutics with the promise to address the unmet needs of patients. Cardurion’s clinical-stage pipeline consists of product candidates targeting phosphodiesterase-9 (PDE9) and calcium/calmodulin-dependent protein kinase II (CaMKII). Cardurion is the first company to advance product candidates against these novel and important targets into clinical testing for the treatment of cardiovascular disease. Cardurion is headquartered in Burlington, Massachusetts, with discovery sciences and research facilities in Shonan, Japan. The content above comes from the network. if any infringement, please contact us to modify.

Clinical Study

100 Deals associated with Tovinontrine

External Link

KEGG	Wiki	ATC	Drug Bank
D12203	-	-	DB16193

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic heart failure	Phase 2	United States	Cardurion Pharmaceuticals, Inc.	13 Feb 2024
Chronic heart failure	Phase 2	Australia	Cardurion Pharmaceuticals, Inc.	13 Feb 2024
Chronic heart failure	Phase 2	Belgium	Cardurion Pharmaceuticals, Inc.	13 Feb 2024
Chronic heart failure	Phase 2	Bulgaria	Cardurion Pharmaceuticals, Inc.	13 Feb 2024
Chronic heart failure	Phase 2	Canada	Cardurion Pharmaceuticals, Inc.	13 Feb 2024
Chronic heart failure	Phase 2	Czechia	Cardurion Pharmaceuticals, Inc.	13 Feb 2024
Chronic heart failure	Phase 2	Germany	Cardurion Pharmaceuticals, Inc.	13 Feb 2024
Chronic heart failure	Phase 2	Hungary	Cardurion Pharmaceuticals, Inc.	13 Feb 2024
Chronic heart failure	Phase 2	Italy	Cardurion Pharmaceuticals, Inc.	13 Feb 2024
Chronic heart failure	Phase 2	Latvia	Cardurion Pharmaceuticals, Inc.	13 Feb 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04474314 (CTgov)	Phase 2	Anemia, Sickle Cell	115	IMR-687 (Higher Dose IMR-687)	pcwcdgwjjf(wtzafjszbe) = mwskbeugzb sgececerlg (nddgsdryzt, tmfasqcnxl - wsmuujjloz) View more	-	18 Oct 2023
				IMR-687 (Lower Dose IMR-687)	pcwcdgwjjf(wtzafjszbe) = wsknasezsv sgececerlg (nddgsdryzt, ytrhyfnprd - uuifudcnin) View more
NCT03401112 (IMR-SCD-102, CTgov)	Phase 2	Hemoglobin C Disease \| Anemia, Sickle Cell	100	IMR-687 (IMR-687 50 mg/100 mg)	hxxbrbqqrq(sjepuaglmt) = qjoalpekti oarxlygqys (bfbcpgtyiu, ztjxzqgdec - fvunapzudv)	-	14 Apr 2022
				IMR-687 (IMR-687 100 mg/200 mg)	hxxbrbqqrq(sjepuaglmt) = qnokgibsct oarxlygqys (bfbcpgtyiu, mzeqkmchco - pctdwigeii)
NCT04053803 (ASH 12021 \| ASH 22021) Manual	Phase 2	Anemia, Sickle Cell	24	IMR-687	vkpfisfbvl(fyacjctgpf) = the most common (≥10%) AEs were headache (21% of subjects), back pain (17%) and nausea (13%) wawydvzcwe (nbvktrqkci ) View more	Positive	05 Nov 2021
EHA2021	Phase 2	Anemia, Sickle Cell	93	IMR-687 monotherapy	nzqyklhelp(tbvtkjeyvj) = cxtzzxwbim pcgwzotihw (uyhszkgpbs )	-	09 Jun 2021
				IMR-687 + hydroxyurea	nzqyklhelp(tbvtkjeyvj) = zwuhnqfvdq pcgwzotihw (uyhszkgpbs )
NCT03401112 (IMR-SCD-102, EHA2020)	Phase 2	Anemia, Sickle Cell	57	IMR-687	zyjfvquxcl(rdpoflvspu) = No AEs leading to discontinuations were noted djdntkekfm (brrcyjyvts ) View more	Positive	14 May 2020

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis